Lyndsay N. Harris
0000-0002-9774-6719
Publication & Citation Trends
Publications
0 total
Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2.
Cited by 0
Semantic Scholar
Larotrectinib in Patients With Tumors With NTRK Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-Z1E.
Cited by 0
Semantic Scholar
Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H.
Cited by 0
Semantic Scholar
Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol Z1K.
Cited by 1
Semantic Scholar
Digital pathology imaging artificial intelligence in cancer research and clinical trials: An NCI workshop report
Cited by 2
Semantic Scholar
PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.
Cited by 1
Semantic Scholar
Framework to Select Multi-Cancer Detection Assays in the National Cancer Institute’s Vanguard Study
Cited by 1
Semantic Scholar
Abstract CT227: Quantum mechanics-based multi-tensor AI/ML discovery of a whole-transcriptome predictor of response and survival in patients treated with dabrafenib and trametinib in the tumor-agnostic small-cohort NCI-MATCH subprotocol H with validation in three tumor types in TCGA
Cited by 0
Semantic Scholar
Research Topics
Cancer Genomics and Diagnostics
(144)
HER2/EGFR in Cancer Research
(137)
Lung Cancer Treatments and Mutations
(102)
Breast Cancer Treatment Studies
(83)
Colorectal Cancer Treatments and Studies
(79)
Affiliations
Rutgers, The State University of New Jersey
Cleveland State University
Boston University
University of Vermont
University of North Carolina at Chapel Hill